# Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

> **NCT01650545** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 21 (actual)

## Conditions studied

- Disorder Related to Lung Transplantation
- Bronchiolitis Obliterans
- Decreased Immunologic Activity
- Chronic Rejection of Lung Transplant

## Interventions

- **DRUG:** Liposomal aerosol cyclosporine
- **OTHER:** standard immune suppression, oral

## Key facts

- **NCT ID:** NCT01650545
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2015-08
- **Final completion:** 2019-11
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01650545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01650545, "Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01650545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*